IPHA Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat DBV Technologies SA's return on equity of --.

Innate Pharma SA has a consensus price target of $8.02, signalling upside risk potential of 313.4%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 185.08%. Given that Innate Pharma SA has higher upside potential than DBV Technologies SA, analysts believe Innate Pharma SA is more attractive than DBV Technologies SA.

Innate Pharma SA has a beta of 0.334, which suggesting that the stock is 66.567% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than DBV Technologies SA's net income of -$23M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 11.60x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to Innate Pharma SA's net margin of -9.55%. Innate Pharma SA's return on equity of -72.79% beat Edap TMS SA's return on equity of -39.5%.

Innate Pharma SA has a consensus price target of $8.02, signalling upside risk potential of 313.4%. On the other hand Edap TMS SA has an analysts' consensus of $8.50 which suggests that it could grow by 548.86%. Given that Edap TMS SA has higher upside potential than Innate Pharma SA, analysts believe Edap TMS SA is more attractive than Innate Pharma SA.

Innate Pharma SA has a beta of 0.334, which suggesting that the stock is 66.567% less volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.124, suggesting its less volatile than the S&P 500 by 87.615%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $21.7M. Innate Pharma SA's net income of -- is lower than Edap TMS SA's net income of -$2.1M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 11.60x versus 0.71x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Genfit SA's return on equity of --.

Innate Pharma SA has a consensus price target of $8.02, signalling upside risk potential of 313.4%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 200.01%. Given that Innate Pharma SA has higher upside potential than Genfit SA, analysts believe Innate Pharma SA is more attractive than Genfit SA.

Innate Pharma SA has a beta of 0.334, which suggesting that the stock is 66.567% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.243%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Genfit SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 11.60x versus 5.83x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of -- compared to Innate Pharma SA's net margin of 6.54%. Innate Pharma SA's return on equity of -72.79% beat Sanofi SA's return on equity of 7.55%.

Innate Pharma SA has a consensus price target of $8.02, signalling upside risk potential of 313.4%. On the other hand Sanofi SA has an analysts' consensus of $63.97 which suggests that it could grow by 26.52%. Given that Innate Pharma SA has higher upside potential than Sanofi SA, analysts believe Innate Pharma SA is more attractive than Sanofi SA.

Innate Pharma SA has a beta of 0.334, which suggesting that the stock is 66.567% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.246%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi SA offers a yield of 7.79% to investors and pays a quarterly dividend of $2.04 per share. Innate Pharma SA pays -- of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Innate Pharma SA quarterly revenues are --, which are smaller than Sanofi SA quarterly revenues of $8.1B. Innate Pharma SA's net income of -- is lower than Sanofi SA's net income of $531.9M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Sanofi SA's PE ratio is 20.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 11.60x versus 2.64x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.